ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Moderate Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $77.33.

A number of research analysts recently weighed in on ANIP shares. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. Truist Financial lifted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in ANI Pharmaceuticals during the second quarter worth approximately $65,000. Ridgewood Investments LLC bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $85,000. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at $106,000. XTX Topco Ltd bought a new stake in ANI Pharmaceuticals in the second quarter worth $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in ANI Pharmaceuticals during the first quarter worth $218,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.9 %

NASDAQ ANIP opened at $59.83 on Thursday. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.26 billion, a P/E ratio of -108.78 and a beta of 0.71. The stock’s 50-day moving average price is $58.51 and its 200-day moving average price is $61.42.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.05 EPS. On average, equities research analysts predict that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.